Study on Patented Non-Opioid MKO Melt® Reported in Leading Peer-Reviewed Anesthesia Journal

Tailwinds' Take: MELT is a very intriguing spinoff from Harrow that has large potential through a non-opioid product that has been prescribed over 250K...

The Biden Rally

As most of my readers know, I reserve Saturday mornings for writing my weekly newsletter. This week, however, Saturday morning marks the arrival of...

Harrow Health Third Quarter 2020 Letter to Stockholders

Tailwinds' Take: below are the key pieces of Harrow's letter to investors. Harrow has done a great job managing through Covid-19 and the Company...

Post Traumatic Investment Disease Redux? Nah, Just A Dose Of Reality

Having survived the rocky cliffs of Moab, I think I jinxed myself with last week's cover photo asking "What could go wrong?" Turns out...

The Final Push…

Like the debate, 2020 has been a sh**-show. Pandemics, political divisiveness, fires...it's not been a beach party to say the least. Yet, here we stand...

This Week at Tailwinds

Stocks continued to climb the proverbial wall of worry last week, with the S&P briefly managing to touch an all-time high and the Russell...

Harrow Reports 2nd Quarter Earnings

Harrow released their 2nd quarter results today along with a letter to shareholders, which can be found here. The letter is a great read...

EyePoint Pharmaceuticals and Harrow Health’s ImprimisRx Announce U.S. Commercial Alliance for DEXYCU®

WATERTOWN, Mass. and NASHVILLE, Tenn., Aug. 04, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative...

Leading Peer-Reviewed Journal Publishes Clinical Study on ImprimisRx’s Combination Prescription Eyedrops

SAN DIEGO, July 13, 2020 (GLOBE NEWSWIRE) -- ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, a wholly-owned subsidiary of Harrow Health,...

Previewing the 2nd Half of 2020…and Other Updates From The Week

Greetings from...wait for it...Ashland Oregon. Yes, it was so good, we came back for more. The weather here is great, the riding is outstanding...

Summer is Coming

When you receive this newsletter, it will be June 21st, the official start of summer. Typically for stocks you have a summer doldrums, "sell...

This Week’s Recap: Skinny Trails, Anixa Looks Primed, Atomera Launching

As most readers know by now, I love mountain biking. It's great exercise and there's a tremendous thrill to hitting a difficult stretch of...

Harrow Health, Inc. Letter to Stockholders

To the Stockholders of Harrow Health, Inc, I’ll start by conveying our sincerest wishes of good health. Thankfully, our most valuable assets, our employees in...

Eton Pharmaceuticals Confirms First-to-File Patent Challenge on Elcys (Cysteine Hydrochloride Injection)

DEER PARK, Ill., May 07, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today disclosed that...

IF Alpha?

My biggest concern last fall was, "what if Bernie gets into office?" This fear was driven partially by the fact that the market would...

In Case You Missed It…Interesting Information From Last Week

Here's an interesting piece of news on Patriot One (PTOTF). If you recall, a little over a year ago, Patriot formed a JV to...

ImprimisRx® Announces Exclusive Agreement with Doxy.me to Provide Healthcare Professionals with Telemedicine Services

NASHVILLE, Tenn., March 24, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) and ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding...

It’s Definitely a Beer Market

Sometimes a typo can hit the sweet spot, right? When I got the text that we're entering a beer market...well, let's just say that...

Harrow Health Publishes Fourth Quarter 2019 Letter to Stockholders

Tailwinds' Take: Harrow continues to build a powerhouse in the compounding business with major upside from their subsidiaries. This is a long-term multi-year hold...

Harrow Gaining Traction…

Tailwinds' Take: this is the third supply agreement announced in the last week by Imprimis, Harrow's wholly owned subsidiary. Between the three agreements, they...

ImprimisRx® Announces Supply Agreement with iOR Partners

Tailwinds' Take: more good news for Harrow's ophthalmology division. Their core business continues to execute well. SAN DIEGO, March 09, 2020 (GLOBE NEWSWIRE) -- ImprimisRx,...

ImprimisRx® Announces Supply Agreement with Vision Center Network of America (VCNA)

Tailwinds' Take: positive news as HROW's core business ramps in the stated direction of $100M in annual revenue. Expect a lot more catalysts for...

Thoughts From Last Week

This feels like a very strange time in the market. Usually markets overreact to news. Violent swings to extreme levels are the common occurrence...

Eton Pharmaceuticals Provides Update on ET-105 Program

Tailwinds' Take: while this delays the approval, it's not a serious impediment and we still expect to see the NDA approved in 2020. Any...

Slogging Through Winter

I was skiing outside Seattle last weekend. Steven's Pass ski resort, to be precise. They have gotten a lot of snow up there this...

Eton Pharmaceuticals and Xellia Pharmaceuticals Announce Biorphen® (phenylephrine HCl) Co-Promotion Agreement

Tailwinds' Take: Eton is executing on their strategy as this announcement demonstrates that Biorphen is gaining traction in the market. We continue to believe owning...

Visions of 2020

This last week was actually a very good week for the Tailwinds' portfolio. Despite the overall quiet of a holiday week (or maybe because...

ImprimisRx’s FDA-Registered Outsourcing Facility Issued California License

SAN DIEGO, Dec. 10, 2019 (GLOBE NEWSWIRE) -- ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, a wholly-owned subsidiary of Harrow...

November Review

Was my sigh of relief audible everywhere? I've been doing this long enough to know that markets are cyclical and that the point of...

Deep Fried Turkey

Those who know me well are well aware that Wednesdays are my favorite night of the week. That's the night I go out mountain...

Recapping The Recent Earnings Reports

The last couple weeks have seen a slew of earnings reports and, more importantly, investor update calls from companies in the Tailwinds Universe. Importantly...

Harrow Health, Inc. Letter to Stockholders

Harrow reported earnings on Wednesday, November 13th. They also, for the first time, published a shareholder letter. This letter tells the complete story of...

Show Me The Money

As the stock market hits new highs on all the major indexes seemingly daily, it appears that the market has moved to a “risk...

Harrow Could Be Your Holiday Bonus

As we head into the home stretch of 2019 the market for microcap stocks seems to have turned around. This time last year it...

Volatility Creating Opportunity…

I tend to be very much a buy and hold investor. I take positions, add to them as I gain confidence and generally let...

Fall Investor Preview Along With A Belated August Recap

I’ve held off on my August recap much like a war veteran will refrain from telling tales from the trenches. Not that my experiences...

Harrow: CMS Approves Prescribing Tri-Moxi

Recently the Centers for Medicare & Medicaid Services ("CMS") issued an update to the Hospital Outpatient Prospective Payment System. This updated guidance, that has...

If I Had A Nickel For Every Buying Opportunity…

The path to being a good investor is to be able to see what the future holds and place your bets accordingly. If you...

Trade Alert, August 15, 2019, Harrow

~ Trade Alerts are sent to premium subscribers in real time. This alert was sent out yesterday, however I feel it should be shared...

Harrow Health Announces Second Quarter 2019 Results

NASHVILLE, Tenn., Aug. 14, 2019 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today reported results for the second quarter 2019. Second Quarter 2019 and...

Recapping The Week That Was…And Looking Towards Next

This was a very hectic week in the market, with major swings in the indexes and in our universe of smaller companies. Earnings season...

Harrow Health Forms Stowe Pharmaceuticals Subsidiary to Develop Broad Spectrum Anti-Microbial Ophthalmic and Otic...

Tailwinds' Take: add another subsidiary to the list of companies formed under the Harrow umbrella. Potential market of $2B they are looking to address....

Harrow Health Announces Launch of Mayfield Pharmaceuticals

Tailwinds' Take: the HROW machine just keeps chugging along. Mayfield could be the most exciting spinoff yet, with multi-billion potential. The markets they're going...

Markets Trade Down In May…June Preview

I'm not sure why, but it seems that every time I feel the Tailwinds' Portfolio is poised for big gains, the market enters a...

B Riley, Day One

Today was the first day of the B Riley Conference in Los Angeles at the Beverly Hilton, a hotel that has a 60's feel...

Harrow Comes Out of Allergan Lawsuit Unscathed

In late-breaking news on Thursday afternoon, a jury has ruled in the case of Allergan vs. Imprimis Pharmaceuticals. If you recall, Allergan had been...

Harrow Health Announces First Quarter 2019 Financial Results

SAN DIEGO, May 09, 2019 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today reported results for the first quarter 2019. First Quarter 2019 and...

ImprimisRx to Introduce New Formulations at Cataract & Refractive Surgery Annual Meeting

SAN DIEGO, April 30, 2019 (GLOBE NEWSWIRE) -- ImprimisRx, the ophthalmology-focused pharmaceutical compounding subsidiary of Harrow Health, Inc. (NASDAQ: HROW), today announced its participation...

Harrow Wins Another Battle In Legal Tussle With Allergan

This week Harrow won a partial summary judgement in their legal tussling with Allergan. This incremental positive supports the companies long-term business model and...

KKR’s Deal With Flying L Validates Harrow

It's always nice when some of the smartest people in the world tell you that what you're doing makes sense. In the case of...

BAUSCH HEALTH ACQUIRES ETON PHARMACEUTICALS’ EM-100 INVESTIGATIONAL EYE DROP FOR THE TREATMENT OF ITCHY...

Tailwinds' Take: this is a big deal for ETON, a company in which Harrow owns 3.5 million shares and has a royalty agreement. There...

Melt Pharmaceuticals Improves Patent Estate for Sublingual Non-Opioid Pain and Sedation Formulations

Tailwinds' Take: we think MELT will end up bing a home run for Harrow, which is building a portfolio of solid companies. SAN DIEGO and...

Harrow Health Subsidiary, Mayfield Pharmaceuticals, Inc., Acquires Patented Dyspareunia Drug Candidate and Other Intellectual...

Tailwinds' Take: this acquisition positions Mayfield as the next subsidiary to be spun out from Harrow. The value of HROW keeps increasing with each...

What The MELT Financing Means To HROW

Today in a press release, Harrow announced the Series A financing of their (formerly) wholly owned subsidiary, Melt Pharmaceuticals. This is a very positive...

What To Put In Your Stockings: December Preview

This weekend we'll be hanging our stockings on the mantel. Come Christmas morning, they'll be lying on the floor, overflowing with presents. At least,...

Imprimis; Priming the Pumps for a Big 2019

If you've been paying attention to me, you know that I've been very bullish on Imprimis Pharmaceuticals (IMMY). In particular, my thinking was that...

Imprimis Pharmaceuticals Announces Third Quarter 2018 Results

SAN DIEGO, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) today reported results for the third quarter 2018. Third Quarter 2018 and...

October Review, Earnings Preview

October has a reputation for being a bad month to own stocks. For the current generation of investors, this reputation was earned primarily from...

Imprimis Pharmaceuticals’ Subsidiary Melt Pharmaceuticals Initiates Clinical Development Program for its Patented Non-Opioid and...

Tailwinds' Take: Melt is potentially the hidden gem in the Imprimis portfolio. I don't think the market equates any significant value to this subsidiary,...

Imprimis Primed For Big Rally

On Thursday evening, one of Tailwinds' readers, sensing a rally, asked me which stock in the TW universe had the following three characteristics: Down...

Imprimis Pharmaceuticals Announces Second Quarter 2018 Results

SAN DIEGO, Aug. 6, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) today reported results for the second quarter 2018. Notable Highlights from the Second Quarter of 2018: ...

Imprimis Announces Multi-Center Clinical Trial for Dropless® TriMoxi™ (Triamcinolone Acetonide-Moxifloxacin for injection) Formulation in...

SAN DIEGO, Aug. 1, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) through its ImprimisRx ophthalmology business today announced its Canadian partner, Advanced Dosage Forms Inc., will...

ImprimisRx’s Dropless® Steroid and Antibiotic Intravitreal Injection Featured in the Prestigious Journal of Cataract...

SAN DIEGO, May 30, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc.'s (NASDAQ: IMMY) ophthalmology compounding division, ImprimisRx, is pleased to announce the findings from a study published...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.